Sugi Predict

Sugi Predict / Compounds / SCHEMBL788056

SCHEMBL788056

SCHEMBL788056

O=[N+]([O-])c1cc(Br)cc(C(F)(F)F)c1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 4/20 0.47
▸ CYP3A4 P08684 3/20 0.47
▸ TSHR P16473 3/20 0.47
▸ TDP1 Q9NUW8 2/20 0.47
▸ HPGD P15428 1/20 0.47
▸ ALOX15 P16050 1/20 0.47
▸ HIF1A Q16665 1/20 0.47
▸ TXNRD1 Q16881 1/20 0.47
▸ TXNRD3 Q86VQ6 1/20 0.47
▸ TXNRD2 Q9NNW7 1/20 0.47
▸ NOTUM Q6P988 1/20 0.41
▸ KIF11 P52732 2/20 0.41
▸ P2RX1 P51575 3/20 0.40
▸ CYP19A1 P11511 1/20 0.40
▸ PTPN5 P54829 1/20 0.40
▸ P2RX4 Q99571 1/20 0.40
▸ P2RX7 Q99572 1/20 0.40
▸ TMPRSS4 Q9NRS4 1/20 0.38
▸ MAPK1 P28482 1/20 0.38
▸ ACP1 P24666 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29698750 1.00 ALDH1A1 (0.47) ALDH1A1CYP3A4TSHRTDP1HPGD
SCHEMBL1996062 0.86 ALDH1A1 (0.55) ALDH1A1CYP3A4TSHRTDP1HPGD
SCHEMBL1005841 0.86 TSHR (0.55) ALDH1A1CYP3A4TSHRTDP1HPGD
SCHEMBL13031098 0.85 HTT (0.41) ALDH1A1CYP3A4TSHRTDP1CYP19A1
Hydrochloric Acid SCHEMBL28212666 0.84 TSHR (0.53) ALDH1A1CYP3A4TSHRTDP1HPGD
Hydrazine SCHEMBL28307217 0.82 TSHR (0.52) ALDH1A1CYP3A4TSHRTDP1HPGD
SCHEMBL30170847 0.81 ACP1 (0.40) ALDH1A1CYP3A4P2RX1CYP19A1ACP1
SCHEMBL1530129 0.81 HTT (0.47) ALDH1A1CYP3A4TSHRTDP1HPGD
SCHEMBL219410 0.79 CYP19A1 (0.55) ALDH1A1CYP3A4TSHRCYP19A1ACP1
SCHEMBL1026447 0.79 CYP19A1 (0.62) ALDH1A1CYP3A4TSHRCYP19A1ACP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 149 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115991873-A Low-dielectric fluorinated aromatic polyimide film and preparation method thereof 慧创(东莞)材料技术有限责任公司 2023-04-21 — — CN claimed
CN-112079729-A Preparation method of 3-alkyl-5-trifluoromethylaniline 海南梵圣生物科技有限公司 2020-12-15 — — CN claimed
US-10392351-B2 Method for preparing nilotinib intermediate SUZHOU LIXIN PHARMACEUTICAL CO., LTD. (CN) 2019-08-27 — — US claimed
US-20160311777-A1 Method for preparing nilotinib intermediate SUZHOU LIXIN PHARMACEUTICAL CO.,LTD (CN) 2016-10-27 — — US claimed
EP-2266961-B1 Process for the synthesis of organic compounds NOVARTIS AG (CH) 2015-10-21 — — EP claimed
CN-102180796-A Method for synthesizing organic compounds NOVARTIS AG 2011-09-14 — — CN claimed
EP-2292607-A2 Process for the synthesis of organic compounds Novartis AG (CH) 2011-03-09 — — EP claimed
EP-2266961-A2 Process for the synthesis of organic compounds Novartis AG (CH) 2010-12-29 — — EP claimed
US-20100280257-A1 PROCESS FOR THE SYNTHESIS OF ORGANIC COMPOUNDS ABEL STEPHAN 2010-11-04 — — US claimed
US-20080200692-A1 Process For the Synthesis of Organic Compounds NOVARTIS AG (CH) 2008-08-21 — — US claimed
CN-101189212-A Method for synthesizing organic compounds NOVARTIS AG (CH) 2008-05-28 — — CN claimed
EP-1896426-A2 PROCESS FOR THE SYNTHESIS OF ORGANIC COMPOUNDS Novartis AG (CH) 2008-03-12 — — EP claimed
WO-2006135640-A2 PROCESS FOR THE SYNTHESIS OF ORGANIC COMPOUNDS NOVARTIS AG (CH) 2006-12-21 — — WO claimed
CN-122036689-A Nilotinib preparation method of nylon 苏州特瑞药业股份有限公司 2026-05-15 — — CN disclosed
EP-4667458-A1 PHARMACEUTICAL COMPOSITION FOR TREATMENT OF CANCER, COMPRISING SOS1 INHIBITOR AND ANTICANCER DRUG Kanaph Therapeutics Inc. (KR) 2025-12-24 — — EP disclosed
EP-4667464-A1 AZOLYLPYRIDINE PYRIDAZINONE AMIDE AS SOS1 INHIBITOR Cyrus Therapeutics Inc. (KR) 2025-12-24 — — EP disclosed
US-20060128734-A1 Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases FLOERSHEIMER ANDREAS 2006-06-15 — — US disclosed
CN-1656073-A Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases NOVARTIS AG (CH) 2005-08-17 — — CN disclosed
EP-1511730-A2 DIARYL UREA DERIVATIVES USEFUL FOR THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES Novartis AG (CH) 2005-03-09 — — EP disclosed
WO-2003099771-A2 DIARYL UREA DERIVATIVES USEFUL FOR THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES NOVARTIS AG (CH) 2003-12-04 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080200692-A1 Process For the Synthesis of Organic Compounds ODC1, AZI2, NISCH ALDH1A1 793/4885CYP3A4 18/4885TSHR 2916/4885
US-10392351-B2 Method for preparing nilotinib intermediate ABL1, PRMT5, NPM1 ALDH1A1 3411/4885CYP3A4 198/4885TSHR 1720/4885
US-20100280257-A1 PROCESS FOR THE SYNTHESIS OF ORGANIC COMPOUNDS ODC1, AZI2, NISCH ALDH1A1 793/4885CYP3A4 18/4885TSHR 2916/4885
US-20060128734-A1 Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases UCK2, PRKDC, PRKACA ALDH1A1 3040/4885CYP3A4 4429/4885TSHR 3952/4885
US-20160311777-A1 Method for preparing nilotinib intermediate ABL1, PRMT5, DNMT3A ALDH1A1 3586/4885CYP3A4 195/4885TSHR 1410/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.